The Beacon Installed on the B-SCREEN Platform at IHU Méditerranée Infection

A platform at the heart of therapeutic antibody discovery

The B-SCREEN platform acts as a true accelerator of scientific innovation. It enables the identification and characterization of monoclonal antibodies with strong clinical potential from patient samples.

Thanks to high-throughput screening enabled by the Beacon™ technology, researchers can perform in-depth analyses of B- and T-cell immune repertoires and rapidly identify cells producing antibodies of interest.

This approach relies on a suite of complementary tools enabling:

• in-depth analysis of BCR and TCR repertoires,

• precise characterization of immune subpopulations,

• antibody cloning and production,

• as well as comprehensive functional assays (specificity, affinity, ligand blocking, and cellular functions).

Bridging the gap between discovery and clinical application

By combining these advanced technological capabilities, B-SCREEN helps bridge the gap between scientific discovery and therapeutic innovation.

While the platform directly contributes to infectious disease research, its applications also extend to other key areas of immunology, including:

• autoimmune diseases,

• inflammatory diseases,

• and immuno-oncology.

This approach is fully aligned with the strategy of the Marseille Immunology Biocluster, which aims to accelerate the discovery and development of new immunotherapies by connecting fundamental research, clinical research, and industrial innovation.

A structuring collaboration for the Marseille ecosystem

The installation of the Beacon technology on the B-SCREEN platform illustrates the strong collaborative dynamic among scientific stakeholders in the region.

By bringing together technological infrastructures, clinical resources, and immunology expertise, this initiative strengthens the Marseille ecosystem’s ability to transform scientific discoveries into concrete therapeutic innovations for the benefit of patients.